Percutaneous radio frequency ablation of renal masses: Results at a 2-year mean followup

Ioannis M. Varkarakis, Mohamad E Allaf, Takeshi Inagaki, Sam B. Bhayani, David Y. Chan, Li Ming Su, Thomas W. Jarrett, Louis R. Kavoussi, Stephen B. Solomon

Research output: Contribution to journalArticle

Abstract

Purpose: We describe our experience with and results of percutaneous computerized tomography guided radio frequency ablation (RFA) for small (less than 4 cm) renal tumors at a 2-year mean followup. Materials and Methods: A total of 49 patients (60 renal tumors) with a mean age of 63.9 years underwent percutaneous RFA. Indications for RFA were severe comorbidities or previous abdominal surgery precluding operative management, or hereditary conditions predisposing to multiple tumor recurrence. Persistent enhancement on initial followup imaging was considered incomplete treatment and all such patients underwent biopsy and were offered repeat RFA. Enhancement or enlargement on subsequent imaging was considered tumor recurrence and these patients were counseled regarding further therapy. Results: Three patients (4 tumors) were excluded from evaluation due to death from unrelated causes or loss to followup. A total of 46 patients (56 tumors) were available for evaluation at a mean followup of 27.5 months (range 12 to 48). Six tumors were incompletely treated with the first RFA and successfully treated with a second session. Recurrences after successful initial treatment were seen in 3 of 46 patients. These recurrences developed 24, 25 and 31 months following RFA, respectively, and all occurred in patients with a central tumor of 3.0 cm or greater. Overall local control was achieved in 94.6% of tumors (53 of 56). Conclusions: RFA is an emerging alternative treatment modality for small renal tumors. Larger (greater than 3.0 cm) central tumors represent unique technical challenges, making these tumors more prone to recurrence. Long-term followup is needed to establish the oncological durability of this technique.

Original languageEnglish (US)
Pages (from-to)456-460
Number of pages5
JournalJournal of Urology
Volume174
Issue number2
DOIs
StatePublished - Aug 2005

Fingerprint

Radio
Kidney
Neoplasms
Recurrence
Therapeutics
Comorbidity
Cause of Death
Tomography
Biopsy

Keywords

  • Catheter ablation
  • Kidney
  • Kidney neoplasms
  • Tomography, x-ray computed

ASJC Scopus subject areas

  • Urology

Cite this

Varkarakis, I. M., Allaf, M. E., Inagaki, T., Bhayani, S. B., Chan, D. Y., Su, L. M., ... Solomon, S. B. (2005). Percutaneous radio frequency ablation of renal masses: Results at a 2-year mean followup. Journal of Urology, 174(2), 456-460. https://doi.org/10.1097/01.ju.0000165655.91152.c5

Percutaneous radio frequency ablation of renal masses : Results at a 2-year mean followup. / Varkarakis, Ioannis M.; Allaf, Mohamad E; Inagaki, Takeshi; Bhayani, Sam B.; Chan, David Y.; Su, Li Ming; Jarrett, Thomas W.; Kavoussi, Louis R.; Solomon, Stephen B.

In: Journal of Urology, Vol. 174, No. 2, 08.2005, p. 456-460.

Research output: Contribution to journalArticle

Varkarakis, IM, Allaf, ME, Inagaki, T, Bhayani, SB, Chan, DY, Su, LM, Jarrett, TW, Kavoussi, LR & Solomon, SB 2005, 'Percutaneous radio frequency ablation of renal masses: Results at a 2-year mean followup', Journal of Urology, vol. 174, no. 2, pp. 456-460. https://doi.org/10.1097/01.ju.0000165655.91152.c5
Varkarakis, Ioannis M. ; Allaf, Mohamad E ; Inagaki, Takeshi ; Bhayani, Sam B. ; Chan, David Y. ; Su, Li Ming ; Jarrett, Thomas W. ; Kavoussi, Louis R. ; Solomon, Stephen B. / Percutaneous radio frequency ablation of renal masses : Results at a 2-year mean followup. In: Journal of Urology. 2005 ; Vol. 174, No. 2. pp. 456-460.
@article{e4c23285d7104cd192aa7ae32f070eaf,
title = "Percutaneous radio frequency ablation of renal masses: Results at a 2-year mean followup",
abstract = "Purpose: We describe our experience with and results of percutaneous computerized tomography guided radio frequency ablation (RFA) for small (less than 4 cm) renal tumors at a 2-year mean followup. Materials and Methods: A total of 49 patients (60 renal tumors) with a mean age of 63.9 years underwent percutaneous RFA. Indications for RFA were severe comorbidities or previous abdominal surgery precluding operative management, or hereditary conditions predisposing to multiple tumor recurrence. Persistent enhancement on initial followup imaging was considered incomplete treatment and all such patients underwent biopsy and were offered repeat RFA. Enhancement or enlargement on subsequent imaging was considered tumor recurrence and these patients were counseled regarding further therapy. Results: Three patients (4 tumors) were excluded from evaluation due to death from unrelated causes or loss to followup. A total of 46 patients (56 tumors) were available for evaluation at a mean followup of 27.5 months (range 12 to 48). Six tumors were incompletely treated with the first RFA and successfully treated with a second session. Recurrences after successful initial treatment were seen in 3 of 46 patients. These recurrences developed 24, 25 and 31 months following RFA, respectively, and all occurred in patients with a central tumor of 3.0 cm or greater. Overall local control was achieved in 94.6{\%} of tumors (53 of 56). Conclusions: RFA is an emerging alternative treatment modality for small renal tumors. Larger (greater than 3.0 cm) central tumors represent unique technical challenges, making these tumors more prone to recurrence. Long-term followup is needed to establish the oncological durability of this technique.",
keywords = "Catheter ablation, Kidney, Kidney neoplasms, Tomography, x-ray computed",
author = "Varkarakis, {Ioannis M.} and Allaf, {Mohamad E} and Takeshi Inagaki and Bhayani, {Sam B.} and Chan, {David Y.} and Su, {Li Ming} and Jarrett, {Thomas W.} and Kavoussi, {Louis R.} and Solomon, {Stephen B.}",
year = "2005",
month = "8",
doi = "10.1097/01.ju.0000165655.91152.c5",
language = "English (US)",
volume = "174",
pages = "456--460",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Percutaneous radio frequency ablation of renal masses

T2 - Results at a 2-year mean followup

AU - Varkarakis, Ioannis M.

AU - Allaf, Mohamad E

AU - Inagaki, Takeshi

AU - Bhayani, Sam B.

AU - Chan, David Y.

AU - Su, Li Ming

AU - Jarrett, Thomas W.

AU - Kavoussi, Louis R.

AU - Solomon, Stephen B.

PY - 2005/8

Y1 - 2005/8

N2 - Purpose: We describe our experience with and results of percutaneous computerized tomography guided radio frequency ablation (RFA) for small (less than 4 cm) renal tumors at a 2-year mean followup. Materials and Methods: A total of 49 patients (60 renal tumors) with a mean age of 63.9 years underwent percutaneous RFA. Indications for RFA were severe comorbidities or previous abdominal surgery precluding operative management, or hereditary conditions predisposing to multiple tumor recurrence. Persistent enhancement on initial followup imaging was considered incomplete treatment and all such patients underwent biopsy and were offered repeat RFA. Enhancement or enlargement on subsequent imaging was considered tumor recurrence and these patients were counseled regarding further therapy. Results: Three patients (4 tumors) were excluded from evaluation due to death from unrelated causes or loss to followup. A total of 46 patients (56 tumors) were available for evaluation at a mean followup of 27.5 months (range 12 to 48). Six tumors were incompletely treated with the first RFA and successfully treated with a second session. Recurrences after successful initial treatment were seen in 3 of 46 patients. These recurrences developed 24, 25 and 31 months following RFA, respectively, and all occurred in patients with a central tumor of 3.0 cm or greater. Overall local control was achieved in 94.6% of tumors (53 of 56). Conclusions: RFA is an emerging alternative treatment modality for small renal tumors. Larger (greater than 3.0 cm) central tumors represent unique technical challenges, making these tumors more prone to recurrence. Long-term followup is needed to establish the oncological durability of this technique.

AB - Purpose: We describe our experience with and results of percutaneous computerized tomography guided radio frequency ablation (RFA) for small (less than 4 cm) renal tumors at a 2-year mean followup. Materials and Methods: A total of 49 patients (60 renal tumors) with a mean age of 63.9 years underwent percutaneous RFA. Indications for RFA were severe comorbidities or previous abdominal surgery precluding operative management, or hereditary conditions predisposing to multiple tumor recurrence. Persistent enhancement on initial followup imaging was considered incomplete treatment and all such patients underwent biopsy and were offered repeat RFA. Enhancement or enlargement on subsequent imaging was considered tumor recurrence and these patients were counseled regarding further therapy. Results: Three patients (4 tumors) were excluded from evaluation due to death from unrelated causes or loss to followup. A total of 46 patients (56 tumors) were available for evaluation at a mean followup of 27.5 months (range 12 to 48). Six tumors were incompletely treated with the first RFA and successfully treated with a second session. Recurrences after successful initial treatment were seen in 3 of 46 patients. These recurrences developed 24, 25 and 31 months following RFA, respectively, and all occurred in patients with a central tumor of 3.0 cm or greater. Overall local control was achieved in 94.6% of tumors (53 of 56). Conclusions: RFA is an emerging alternative treatment modality for small renal tumors. Larger (greater than 3.0 cm) central tumors represent unique technical challenges, making these tumors more prone to recurrence. Long-term followup is needed to establish the oncological durability of this technique.

KW - Catheter ablation

KW - Kidney

KW - Kidney neoplasms

KW - Tomography, x-ray computed

UR - http://www.scopus.com/inward/record.url?scp=22144472946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144472946&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000165655.91152.c5

DO - 10.1097/01.ju.0000165655.91152.c5

M3 - Article

C2 - 16006864

AN - SCOPUS:22144472946

VL - 174

SP - 456

EP - 460

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -